More than 30 million people in the United States and Europe have food allergies. Eight percent of U.S. children are estimated to have a food allergy, and one in 13 U.S. children are at risk for life-threatening anaphylaxis, underscoring the urgent need for new therapies and diagnostics to accurately assess and manage patients living with food allergies.
Yet, current food allergy diagnostics have very low accuracy, and as many as 60 percent of patients may be misdiagnosed. AllerGenis has developed its technology using data-driven machine learning and next-generation multiplex immunoassay technology to more precisely diagnose and monitor patients with food allergies. It will be one of the first non-oncologic, precision medicine tools to help providers better diagnose, assess, and manage patients with food allergies.
At AllerGenis, our mission is to bring precision diagnostics to market with an enhanced capability to safely identify, diagnose, and monitor patients throughout the natural history of their allergic disease while providing therapeutic innovators a diagnostic tool with the predictive value required to determine clinical efficacy and therapeutic response over time.